Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of orally administered ibandronic acid, compared with intravenously administered ibandronic acid (Bonviva IV Injection), in patients with osteoporosis in Japan

Trial Profile

Phase III trial of orally administered ibandronic acid, compared with intravenously administered ibandronic acid (Bonviva IV Injection), in patients with osteoporosis in Japan

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibandronic acid (Primary) ; Ibandronic acid
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms MOVEST
  • Sponsors Chugai Pharmaceutical; Taisho Pharmaceutical
  • Most Recent Events

    • 17 Apr 2016 Results of sub-group analysis (n=422) presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 22 Jan 2016 According to Chugai Pharmaceuticals media release, company has filed a new drug application to the MHLW.
    • 22 Jan 2016 Results published in Chugai Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top